Results 251 to 260 of about 10,262,815 (318)

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

circVDJ-seq for T cell clonotype detection in single-cell and spatial multi-omics. [PDF]

Genome Med
Plumbom I, Obermayer B, Raspe R, Pascual-Reguant A, Theurillat I, Pentimalli TM, Hsieh YH, Gil M, Dietrich C, Seeger-Zografakis M, Quedenau C, Wilde J, Braeuning C, Fischer C, Schuelke M, Seitz V, Ludwig LS, Eggert A, Rajewsky N, Borodina T, Beule D, Altmueller J, Radbruch H, Hauser AE, Conrad T.   +24 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

APOBEC2 deficiency disrupts hematopoietic lineage commitment, resulting in emergence of dual identity lymphocytes in mice and humans. [PDF]

Proc Natl Acad Sci U S A
Moris Amro E, Gkougkousis C, Seebass JG, Telioglu I, Bakr A, Lorenzo JP, Abolhassani H, Altenhofen J, Berntson L, Ruf S, Hammarström L, Pan-Hammarström Q, Imbusch CD, Papavasiliou FN.   +13 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Longitudinal spatial neutrophil profiling during ACT in murine melanoma reveals distinct lymph node infiltration patterns. [PDF]

NPJ Syst Biol Appl
van der Voort G, Effern M, Yong MCR, Kiwitz L, Turiello R, Leonardelli S, Ng S, Corvino D, Bald T, Glodde N, Thurley K, Hasenauer J, Hölzel M.   +12 more
europepmc   +1 more source

Targeting TMED4 enhances CD8⁺ T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis. [PDF]

Sci Adv
Wang H, Shi L, Jiang K, Wu S, Jiang Z, Tao Y, Li J, Li X, Liu J, Ni J, Wu EJ, Wu SJ, Chen G, Qin M, Xu L, Lai CH, Aicher A, Ye Y, Heeschen C, Cao YJ, Wu X.   +20 more
europepmc   +1 more source